Precigen Inc. (PGEN) Presents Preclinical Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
April 17, 2023 9:01 AM EDTFirst preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR)
MSLN is overexpressed on multiple solid tumors such as mesothelioma, ovarian cancer and pancreatic cancer
Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells has the potential for an improved safety profile and reduced cost by eliminating the need for checkpoint inhibitor combinationÂ
Single administration of next generation MSLN UltraCAR-T incorporating intrinsic PD-1 blockade resulted in robust UltraCAR-T cell expansion and durable persistence leading to... More
